Calcinosis cutis associated with amyopathic dermatomyositis: Response to intravenous immunoglobulin

Peñate, Yeray; Guillermo, N.; Melwani, P.; Martel, Rosa; Hernández‐Machín, Buenaventura; Borrego, Leopoldo

doi:10.1016/j.jaad.2008.09.051

Cited by 63 publications

(40 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Improvements in cutaneous disease preceded or coincided with muscle improvement, which was evident approximately 15 days after the first infusion of IVIG and peaked between the second and third infusions. A case report of a similar patient responding to IVIG (2 g/kg/month) at a dose of 0.4 g/day for 5 consecutive days with complete resolution of the cutaneous symptoms adds to our background knowledge 3. The patient described in the earlier case report received maintenance treatment with a yearly course of IVIG and has not had recurrence in her disease during a 5-year follow-up.…”

Section: Discussionmentioning

confidence: 81%

Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin

Shahani¹

2012

BMJ Case Reports

View full text Add to dashboard Cite

Dermatomyositis is an inflammatory myopathy and commonly presents with progressive, symmetric proximal muscle weakness and cutaneous findings. Calcinosis is a severe manifestation that can be debilitating. The cutaneous manifestations of dermatomyositis may also develop in the absence of detectable muscle disease, and can persist after the successful treatment of myositis. The author reports a 30-year-old woman with biopsy-proven dermatomyositis who had failed previous trials of azathioprine and methotrexate. Her muscle weakness was controlled with mycophenolate mofetil and prednisone; however, she had recurrent attacks of painful calcinosis. The patient responded to intravenous immune globulin (IVIG) along with intravenous methylprednisone, followed by IVIG for 2 consecutive days each month. This regimen has been effective in preventing recurrence of her calcinosis. This case illustrates the cutaneous manifestation of dermatomyositis, which is often more refractory to treat as compared to the muscle involvement and require additional approaches such as IVIG.

show abstract

Section: Discussionmentioning

confidence: 81%

Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin

Shahani¹

2012

BMJ Case Reports

View full text Add to dashboard Cite

show abstract

“…The number of isolated cases reported that were treated empirically and no organized trial has highlighted the absence of an effective and codified treatment for CC. [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] The following agents have been prescribed: diltiazem, 11 aluminum hydroxide, 12 sodium thiosulfate, 13 colchicine, 14 edathamil, 15 intravenous immunoglobulins, 16 carbon-dioxide laser, 17 warfarin, 18 minocycline, 19 or bisphosphonates, 20-23 achieving variable efficacy and causing significant side effects. Excision of CC that are painful or a source of disability is sometimes proposed, but the topography (distal and periarticular site for SSC) and the extent of the lesions (CVI) can render surgical management difficult.…”

Section: Discussionmentioning

confidence: 99%

Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy

Sultan-Bichat

Menard

Perceau

et al. 2012

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…Data supporting treatment recommendations are limited to case reports and case series which have seldom been validated in more wide-spread use. Potential pharmacologic treatment modalities include warfarin [82], diltiazem [83], IVIG [84], rituximab [85], and infliximab [86]. Colchicine [87], NSAIDs, and local steroids can be used for local inflammation surrounding the calcinosis.…”

Section: Calcinosismentioning

confidence: 99%

Update on Systemic Sclerosis

McCray

Mayes

2015

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a rare autoimmune disease characterized by autoantibody production, small-vessel vasculopathy, and skin and other organ fibrosis. The disease is clinically heterogeneous with most patients having some degree of skin sclerosis with varying organ system involvement. Early disease can be difficult to diagnose, especially with minimal skin sclerosis and absence of anti-nuclear antibody (ANA) positivity; however, studies have demonstrated early diagnosis is important as early treatment could potentially lead to better outcomes. New classification criteria have recently been published that have higher sensitivity for detecting early disease thus allowing for a broader spectrum of patients to be represented in clinical trials. Treatment guidelines have been published based on a limited number of randomized-controlled clinical trials; however, there are ongoing phase II and III clinical trials with novel agents that are promising and will change the treatment landscape over the next decade.

show abstract

Calcinosis cutis associated with amyopathic dermatomyositis: Response to intravenous immunoglobulin

Cited by 63 publications

References 5 publications

Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin

Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin

Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy

Update on Systemic Sclerosis

Contact Info

Product

Resources

About